IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023
Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024
Read more at prnewswire.comWe've received your inquiry. A specialist will reach out within 1 business day.
Start overAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023
Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| THRX | 4.06 | unch | unch |
| Theseus Pharmaceuticals Inc | |||